For many Americans, Scott Gottlieb has become a household name in health care. He is a former commissioner of the Food and Drug Administration. He made frequent media appearances during the Covid-19 pandemic. And in 2019, he oversaw a record number of new personalized medicine approvals. During this opening keynote address, Gottlieb will reveal his latest thinking about the future of personalized medicine and discuss what it needs to advance.

INTRODUCTION | Lauren Silvis, J.D., Senior Vice President, External Affairs, Tempus

KEYNOTE SPEAKER | Scott Gottlieb, M.D., Senior Fellow, American Enterprise Institute; New York Times best-selling author, Uncontrolled Spread: Why COVID-19 Crushed Us and How We Can Defeat the Next Pandemic

Game-changing early detection technologies. Wearable health monitoring devices. Gene editing. Investors see tantalizing possibilities in personalized medicine. But the path to profitability is fraught with challenges. During this session, a panel of investors will consider the future of investment in personalized medicine.

MODERATOR | Jared Whitlock, Features Editor, Endpoints News

Vineeta Agarwala, M.D., Ph.D., General Partner, Andreessen Horowitz

Tess Cameron, Principal, RA Capital Management

Michael J. Pellini, M.D., Managing Partner, Section 32

Many companies are widening the frontiers of personalized medicine. PathAI is using artificial intelligence to advance personalized medicine in pathology. Siemens executives see an expanded role for imaging biomarkers to target therapies to those who will benefit. DNAnexus is using cloud-based computing platforms to inform the development of more precise medical interventions. And at Kyverna Therapeutics, scientists are exploring how to extend the benefits of cell-based immunotherapies to patients with autoimmune diseases. During this session, executives from each of these companies will explain how their work may expand the boundaries of personalized medicine.

MODERATOR | Raju Kucherlapati, Ph.D., Paul C. Cabot Professor of Genetics, Harvard Medical School

Andy Beck, M.D., Ph.D., CEO, PathAI

Peter Maag, Ph.D., CEO, Kyverna Therapeutics

Rangarajan Sampath, Ph.D., Senior Vice President, Head of Center for Innovation in Diagnostics, Siemens Healthineers

Omar Serang, Chief Cloud Officer, DNAnexus

The Annual Award for Leadership in Personalized Medicine recognizes an individual whose contributions in science, business, and policy have helped advance the frontiers of the field. This year’s award goes to Bonnie J. Addario, a tireless patient advocate and co-founder of GO2 for Lung Cancer.

PRESENTER | Michael J. Pellini, M.D., Managing Partner, Section 32

AWARDEE | Bonnie J. Addario, Co-Founder, GO2 for Lung Cancer

Innovators in personalized medicine are struggling to convince health insurance executives that paying more for tests and treatments today will decrease health spending in the future by keeping patients healthier, longer. While serving as Chief Medical Officer for regional health insurer Point32Health from 2011 to March of 2023, Michael Sherman repeatedly broke this bottleneck by signing innovative reimbursement agreements with diagnostics and therapeutics developers who are willing to share in the financial risks of piloting coverage for new medical products. During this session, Sherman will reflect on what it takes to move the reimbursement needle in ways that benefit both patients and health systems.

INTRODUCTION | Cynthia A. Bens, Senior Vice President, Public Policy, Personalized Medicine Coalition

SPEAKER | Michael Sherman, M.D., Venture Partner, RA Capital Management

Diagnostics companies provide a backbone for personalized medicine by developing the tests necessary to target the right preventive and treatment interventions to the right patients at the right times. Testing innovators today face daunting challenges along with promising new opportunities to impact health care. During this panel discussion, industry executives will consider the future of diagnostic test development.

MODERATOR | Kimberly Popovits, Former Chairman, CEO, Genomic Health

Brian Alexander, M.D., CEO, Foundation Medicine

Helmy Eltoukhy, Ph.D., Chairman, co-CEO, Guardant Health

Chad Robins, Chairman, CEO, Adaptive Biotechnologies

Jay G. Wohlgemuth, M.D., Former Chief Medical Officer & Chief Scientific Officer, Quest Diagnostics; Managing Partner, Trusted Health Advisors

The pharmaceutical industry stands four-square behind personalized medicine. PMC’s latest research shows that personalized medicines accounted for at least 25 percent of new U.S. Food and Drug Administration-approved drugs for each of the last eight years. But economic and political landscapes are shifting. During this panel discussion, industry executives will discuss how they are continuing to cultivate their pipelines while adapting to dynamic circumstances across the globe.

MODERATOR | Randy Burkholder, Vice President, Policy and Research, PhRMA

Gabriele Allegri, Global Commercial Head, Precision Medicine, The Janssen Pharmaceutical Companies of Johnson & Johnson

Sarah Hersey, Vice President, Precision Medicine, Bristol Myers Squibb

Steffan Ho, M.D., Ph.D., Vice President, Head of Translational Oncology and Oncology Diagnostics, Pfizer

Tamar Thompson, Vice President, Head of Corporate Affairs, Alexion/AstraZeneca Rare Disease

Leaders in clinical care are eager to understand whether clinical integration programs in personalized medicine will improve the lives of their patients. During this presentation, the Personalized Medicine Coalition will unveil the preliminary results of a study designed to evaluate whether the clinical integration efforts of United States health systems that score higher on a peer-reviewed survey measuring multi-factorial clinical adoption of personalized medicine are driving superior clinical outcomes for their patients.

MODERATOR | Daryl Pritchard, Ph.D., Senior Vice President, Science Policy, Personalized Medicine Coalition

Gary Gustavsen, Partner, Health Advances

For clinical care providers, personalized medicine may present opportunities to improve care for their patients and make better use of scare resources by targeting treatments to those who will benefit. But spearheading the clinical adoption of personalized medicine is anything but easy. During this panel discussion, researchers, business leaders, and clinicians who are intimately involved in the clinical integration of personalized medicine will reflect on the pace of progress in the United States and Europe.

MODERATOR | Howard McLeod, Pharm.D., Managing Director, Clarified Precision Medicine

Antonio L. Andreu, M.D., Ph.D., Scientific Director, European Infrastructure for Translational Medicine (EATRIS)

Thomas Brown, M.D., Chief Medical Officer, Syapse

Catherine Hajek, M.D., Medical Director, Helix; Director, Population Genomics, Sanford Health

Konstantinos Lazaridis, M.D., Executive Director, Center for Individualized Medicine, Mayo Clinic

As a Chief Medical Officer responsible for the health care business of one of the world’s largest technology companies, Amy Abernethy, formerly Principal Deputy Commissioner at the U.S. Food and Drug Administration, sits at the intersection of the rapidly converging industries of medicine, technology, and digital health. During this closing keynote address, Abernethy will explain her vision of a future in which collaborative leaders deploy advanced computational tools, artificial intelligence, and remote data collection technologies to unleash the full potential of personalized medicine for every patient.

INTRODUCTION | Michael Vasconcelles, M.D., Chief Medical Officer, ImmunoGen

KEYNOTE SPEAKER | Amy Abernethy, M.D., Ph.D., Chief Medical Officer, President, Product Development, Verily, an Alphabet company

Sponsored by